January 29, 2026 – ETCTN
CTEP is accepting Letters of Intent (LOIs) to conduct clinical studies using entinostat, a class I histone deacetylase (HDAC) inhibitor, which is being developed by CTEP as an anticancer agent.
DF/HCC Is a Research Consortium
that provides shared resources and a collaborative environment for over 1,100 cancer researchers at 7 Harvard institutions. Learn more about DF/HCC here
Information for DF/HCC members and collaborators
Shared resources available to DF/HCC members
Resources and initiatives for Massachusetts communities
Opportunities for training and career enhancement
Research Funding Opportunities